SEC Filing Summary
Filing identity: The supplied filing is GlycoMimetics, Inc.’s Form 10-Q for the quarter ended March 31, 2022, not a Crescent BioPharma, Inc. filing. The company-name mismatch should be verified.
Business context and reporting period
GlycoMimetics is a clinical-stage biotechnology company developing glycomimetic drugs. Its lead candidate, uproleselan, is being studied for acute myeloid leukemia (AML); the company also has earlier-stage programs including GMI-1687 and GMI-1359. The results below cover the three months ended March 31, 2022, compared with the same 2021 period. The interim financial statements are unaudited.
Financial results and liquidity
| Metric | Q1 2022 | Q1 2021 or comparison |
|---|---|---|
| Revenue | $0 | $1.06 million |
| Research and development expense | $9.60 million | $11.15 million |
| General and administrative expense | $5.06 million | $4.19 million |
| Total costs and expenses | $14.66 million | $15.34 million |
| Net loss | $14.65 million | $14.27 million |
| Basic and diluted loss per share | $0.28 | $0.28 |
| Net cash used in operating activities | $13.70 million | $14.13 million |
| Cash and cash equivalents, March 31 | $76.52 million | $90.25 million at Dec. 31, 2021 |
Operating cash use plus investing outflows of $0.04 million reduced cash by $13.74 million during the quarter. There was no financing cash flow in Q1 2022; Q1 2021 included $9.56 million of net equity proceeds. Total assets were $81.46 million and stockholders’ equity was $68.03 million at March 31. Total liabilities were $13.43 million, including $1.68 million of lease liabilities; the filing reports no debt financing. Remaining office-lease payments were $1.77 million before a $0.09 million present-value adjustment.
No meaningful operating margin is presented: the company had no Q1 2022 revenue and incurred operating expenses of $14.66 million. Interest income was $7,069. No income tax provision or benefit was recorded.
Material changes versus the prior period
- Revenue fell by $1.06 million to zero; Q1 2021 revenue was from clinical-supply sales to Apollomics.
- R&D expense declined $1.54 million, primarily with lower uproleselan clinical-trial costs after enrollment ended, and lower stock-based compensation. Higher uproleselan manufacturing and GMI-1687 toxicity-study costs partly offset the decreases.
- G&A expense rose $0.87 million, primarily due to uproleselan commercial-startup costs, higher patent fees and hiring a Chief Commercial Officer.
- Net loss increased by approximately $0.38 million despite lower total expenses, mainly reflecting the absence of the prior-year revenue.
Outlook, risks and contingencies
- Management reported substantial doubt about the company’s ability to continue as a going concern beyond one year from issuance without additional financing or another funding arrangement. The company has no committed external funding source.
- The filing gives differing cash-runway estimates: one section says existing cash could fund operations into Q2 2023, while another says into Q3 2023. Management cautions that estimates rely on assumptions and cash could be used sooner.
- Management anticipated the overall-survival event trigger in the global Phase 3 uproleselan trial around mid-2023, with top-line data shortly thereafter. The Phase 2 portion of the NCI-sponsored trial had completed enrollment; a planned interim analysis would inform whether it proceeds to Phase 3. COVID-19-related disruption could affect trial timing.
- The company said it was conducting preclinical work to support a planned GMI-1687 IND submission in the first half of 2022. It also reported terminating the GMI-1359 Phase 1b breast-cancer trial in Q4 2021.
- On April 28, 2022, after quarter-end, the company replaced its prior ATM agreement with a new agreement allowing sales of up to $100 million of common stock, subject to company discretion and agreement terms. Potential sales could dilute existing shareholders; the filing reports a 3% sales commission.
- Potential Apollomics development and commercial milestones and royalties remain conditional and uncertain. The filing reports no material legal proceedings and no material change to the previously disclosed risk factors.
Important facts for investors to verify
- Confirm the issuer: the filing identifies GlycoMimetics, Inc., whereas the request metadata identifies Crescent BioPharma, Inc.
- Review the basis and assumptions behind the differing Q2 versus Q3 2023 cash-runway estimates, and the going-concern warning.
- Track the Phase 3 uproleselan event timing, anticipated data disclosure and any effects of COVID-19 or other trial delays.
- Assess future financing needs, ATM sales and potential dilution; the stated $100 million facility is not committed cash already received.
- Monitor Apollomics development progress and whether any contingent milestones, supply revenue or royalties are earned.